Product NDC: | 0185-0714 |
Proprietary Name: | Orphenadrine Citrate, Aspirin and Caffeine |
Non Proprietary Name: | Orphenadrine Citrate, Aspirin and Caffeine |
Active Ingredient(s): | 770; 60; 50 mg/1; mg/1; mg/1 & nbsp; Orphenadrine Citrate, Aspirin and Caffeine |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, MULTILAYER |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0185-0714 |
Labeler Name: | Eon Labs, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA074654 |
Marketing Category: | ANDA |
Start Marketing Date: | 19961231 |
Package NDC: | 0185-0714-05 |
Package Description: | 500 TABLET, MULTILAYER in 1 BOTTLE (0185-0714-05) |
NDC Code | 0185-0714-05 |
Proprietary Name | Orphenadrine Citrate, Aspirin and Caffeine |
Package Description | 500 TABLET, MULTILAYER in 1 BOTTLE (0185-0714-05) |
Product NDC | 0185-0714 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Orphenadrine Citrate, Aspirin and Caffeine |
Dosage Form Name | TABLET, MULTILAYER |
Route Name | ORAL |
Start Marketing Date | 19961231 |
Marketing Category Name | ANDA |
Labeler Name | Eon Labs, Inc. |
Substance Name | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE |
Strength Number | 770; 60; 50 |
Strength Unit | mg/1; mg/1; mg/1 |
Pharmaceutical Classes | Centrally-mediated Muscle Relaxation [PE],Muscle Relaxant [EPC],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient] |